Recently, IgA began to be considered as a key biomarker of immunosuppressive B cells; IgA can encourage the formation of tumor-immunosuppressive environments and reduce the antigen delivery and phagocytosis of tumor cells, and the antibodies produced by IgA can form immune complexes with tumor or non-tumor antigens, interact with immunosuppressive cells, including MDSCs cells, increase inflammatory responses, and encourage immune escape. This evidence concerns the gene CD79A and neoplasm.